Your browser doesn't support javascript.
loading
Association of atrial fibrillation with survival in patients with low-flow low-gradient aortic stenosis with preserved ejection fraction undergoing TAVI.
Nakase, Masaaki; Tomii, Daijiro; Heg, Dik; Praz, Fabien; Stortecky, Stefan; Lanz, Jonas; Reineke, David; Windecker, Stephan; Pilgrim, Thomas.
Afiliación
  • Nakase M; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Tomii D; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Heg D; CTU Bern, University of Bern, Bern, Switzerland.
  • Praz F; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Stortecky S; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Lanz J; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Reineke D; Department of Cardiac Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Windecker S; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Pilgrim T; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Article en En | MEDLINE | ID: mdl-37491693
ABSTRACT

AIMS:

There is limited evidence on the prognostic significance of atrial fibrillation (AF) in patients with low flow, low gradient aortic stenosis with preserved ejection fraction (LFLG-pEF AS). We aimed to evaluate the recovery of stroke volume after transcatheter aortic valve implantation (TAVI) and clinical outcomes in patients with LFLG-pEF AS stratified by presence or absence of AF. METHODS AND

RESULTS:

In a prospective TAVI registry, patients with preserved left ventricular ejection fraction (LVEF ≥ 50%) were stratified according to flow-gradient status and presence of AF. Among 2 259 TAVI patients with preserved LVEF between August 2007 and June 2021, 765 had high-gradient AS (HG AS) and 444 had LFLG-pEF AS. AF was observed in 199 patients with HG AS (26.0%) and 190 patients with LFLG-pEF AS (42.8%). At 1 year, SVi was significantly improved in LFLG-pEF AS patients without AF, while SVi remained low in patients with AF (from 25.9 ± 8.5 mL/m2 to 37.2 ± 9.9 mL/m2 and from 26.8 ± 5.1 mL/m2 to 26.1 ± 9.1 mL/m2, respectively). LFLG-pEF AS patients with AF had an increased risk of 1-year all-cause mortality compared with those without AF (HRadjusted 2.57; 95% CI 1.44-4.59). LFLG-pEF AS patients without AF had similar mortality compared with HG AS patients without AF (HRadjusted 0.85; 95% CI 0.49-1.46).

CONCLUSIONS:

Patients with LFLG-pEF AS and AF experienced no relevant recovery of stroke volume after TAVI, but a more than two-fold increased risk of death compared to patients with HG AS or LFLG-pEF AS without AF. Clinical Trial Registration https//www.clinicaltrials.gov. NCT01368250.
Palabras clave

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Risk_factors_studies Idioma: En Revista: Eur Heart J Qual Care Clin Outcomes Año: 2023 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Risk_factors_studies Idioma: En Revista: Eur Heart J Qual Care Clin Outcomes Año: 2023 Tipo del documento: Article País de afiliación: Suiza